← Back to headlines
argenx Invests $2.2 Billion in Vitiligo Breakthrough with Forte Biosciences Deal
argenx has committed $2.2 billion to a vitiligo breakthrough through a deal with Forte Biosciences, with implications for both companies' stock performance.
29 Jul, 07:45 — 29 Jul, 07:45
Sources
Showing 1 of 1 sources
Related Stories
Climate Catastrophes in Europe Cost Billions, Burdening Citizens
25m ago
Former Google CEO Eric Schmidt Selling Superyacht for €149 Million
26m ago
Berkshire Hathaway's Significant Investment in Alphabet Stock
33m ago
Fabrinet Shares Decline Despite Earnings Beat Due to Margin and Cash Flow Concerns
49m ago